Parabilis follows up Regeneron deal with IPO filing: Public Equity Report

A day after entering a multi-target partnership in which Regeneron committed to purchase equity alongside an upfront payment, Parabilis filed to go public on NASDAQ.

In the deal, announced Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) agreed to pay  Parabilis Medicines Inc. $50 million up front and said it would invest $75 million in Parabilis’ next equity funding. Assuming Parabilis prices its offering, that investment will occur concurrently, but will be priced as a PIPE at a 10% discount to the IPO price...